EP3253766A4 - Composés et procédés pour prévenir ou traiter la mort de cellules capillaires sensorielles - Google Patents

Composés et procédés pour prévenir ou traiter la mort de cellules capillaires sensorielles Download PDF

Info

Publication number
EP3253766A4
EP3253766A4 EP16747385.9A EP16747385A EP3253766A4 EP 3253766 A4 EP3253766 A4 EP 3253766A4 EP 16747385 A EP16747385 A EP 16747385A EP 3253766 A4 EP3253766 A4 EP 3253766A4
Authority
EP
European Patent Office
Prior art keywords
compounds
preventing
methods
cell death
hair cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP16747385.9A
Other languages
German (de)
English (en)
Other versions
EP3253766B1 (fr
EP3253766A2 (fr
Inventor
Julian Simon
Graham Johnson
Edwin W. Rubel
David W. Raible
Mario D. GONZALEZ
Peter C. Meltzer
Weishi Miao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oricula Therapeutics LLC
University of Washington
Fred Hutchinson Cancer Center
Original Assignee
Oricula Therapeutics LLC
University of Washington
Fred Hutchinson Cancer Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oricula Therapeutics LLC, University of Washington, Fred Hutchinson Cancer Research Center filed Critical Oricula Therapeutics LLC
Publication of EP3253766A2 publication Critical patent/EP3253766A2/fr
Publication of EP3253766A4 publication Critical patent/EP3253766A4/fr
Application granted granted Critical
Publication of EP3253766B1 publication Critical patent/EP3253766B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP16747385.9A 2015-02-06 2016-02-05 Composés et procédés pour prévenir ou traiter la mort de cellules capillaires sensorielles Active EP3253766B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562113245P 2015-02-06 2015-02-06
PCT/US2016/016880 WO2016127123A2 (fr) 2015-02-06 2016-02-05 Composés et procédés pour prévenir ou traiter la mort de cellules capillaires sensorielles

Publications (3)

Publication Number Publication Date
EP3253766A2 EP3253766A2 (fr) 2017-12-13
EP3253766A4 true EP3253766A4 (fr) 2018-07-25
EP3253766B1 EP3253766B1 (fr) 2019-09-04

Family

ID=56564889

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16747385.9A Active EP3253766B1 (fr) 2015-02-06 2016-02-05 Composés et procédés pour prévenir ou traiter la mort de cellules capillaires sensorielles

Country Status (11)

Country Link
US (2) US9493482B2 (fr)
EP (1) EP3253766B1 (fr)
JP (1) JP6697808B2 (fr)
KR (1) KR102557184B1 (fr)
CN (1) CN107438613B (fr)
AU (1) AU2016215023B2 (fr)
CA (1) CA2974395C (fr)
DK (1) DK3253766T3 (fr)
ES (1) ES2760373T3 (fr)
HK (1) HK1246791A1 (fr)
WO (1) WO2016127123A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2974395C (fr) 2015-02-06 2023-08-22 University Of Washington Composes et procedes pour prevenir ou traiter la mort de cellules capillaires sensorielles
EP3366683A1 (fr) * 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Amides, acetamides et ureas cycliques pour ouvris les voies de calcium
WO2019046731A1 (fr) * 2017-09-01 2019-03-07 University Of Washington Formes cristallines de composés pour prévenir ou traiter la mort de cellules ciliées sensorielles
WO2020033322A1 (fr) * 2018-08-06 2020-02-13 Fred Hutchinson Cancer Research Center Composés protégeant contre la perte d'audition et procédés associés
US11857551B1 (en) 2020-07-10 2024-01-02 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss
KR20240059256A (ko) * 2022-10-27 2024-05-07 고려대학교 산학협력단 암모늄 락테이트를 유효성분으로 포함하는 난청 예방 또는 치료용 약학 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES457780A1 (es) 1977-04-14 1978-08-16 Made Labor Sa Un procedimiento para la obtencion de 7,10-dimetil-5,9-imi- no-4,5,8,9 - tetrahidrocicloocta (b) tiofenos.
ES462993A1 (es) 1977-10-07 1978-06-01 Made Labor Sa Un procedimiento para la obtencion simultanea de 6,7,10-tri-metil-5,9-imino-4,5,8,9-tetrahidrocicloocta(b)furano y de alfa-2,4,5-trimetilfuro(2,3-f)morfano.
US4174396A (en) 1978-04-03 1979-11-13 Laboratories Made, S.A. 7,10-Dimethyl-5,9-imino-4,5,8,9-tetrahydro-cyclooct[b]thiophenes and a process for obtaining it
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
EP0230654B1 (fr) 1985-12-28 1992-03-18 Sumitomo Pharmaceuticals Company, Limited Préparation pharmaceutique à libération retardée intermittante
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
WO1993009785A1 (fr) 1991-11-22 1993-05-27 Procter & Gamble Pharmaceuticals, Inc. Compositions de risedronate a liberation lente
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5700410A (en) 1992-10-16 1997-12-23 Nippon Shinyaku Co., Ltd. Method of manufacturing wax matrices
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
CA2220451A1 (fr) 1995-05-17 1996-11-21 Cedars-Sinai Medical Center Methodes et compositions pour ameliorer la digestion et l'absorption dans l'intestin grele
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
WO2003002569A1 (fr) 2001-06-29 2003-01-09 Novo Nordisk A/S Procede permettant d'inhiber ptp1b et / ou ptp de lymphocyte t et / ou d'autres ptpases a reste asp en position 48
EP1670804A2 (fr) 2003-09-10 2006-06-21 GPC Biotech AG Composés heterobicycliques ayant une activité pharmaceutique
GB0324653D0 (en) 2003-10-22 2003-11-26 Syngenta Participations Ag Fungicides
JP2007512255A (ja) 2003-11-13 2007-05-17 アンビット バイオサイエンシス コーポレーション キナーゼ調節因子としての尿素誘導体
US20060188445A1 (en) * 2005-02-22 2006-08-24 Fred Hutchinson Cancer Research Center Assay for compounds that protect against sensory hair cell death and compounds identified by same
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US20110158911A1 (en) * 2009-07-01 2011-06-30 Trustees Of Dartmouth College Methods for Screening for Antibiotic Compounds
DK2900674T3 (en) * 2012-09-28 2017-07-03 Univ Washington Through Its Center For Commercialization RELATIONSHIPS AND PROCEDURES FOR PREVENTION, TREATMENT AND / OR PROTECTION AGAINST SENSITIVE CELL DEATH
CA2974395C (fr) 2015-02-06 2023-08-22 University Of Washington Composes et procedes pour prevenir ou traiter la mort de cellules capillaires sensorielles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
KR20180003530A (ko) 2018-01-09
CN107438613A (zh) 2017-12-05
US9493482B2 (en) 2016-11-15
CA2974395A1 (fr) 2016-08-11
CN107438613B (zh) 2020-08-25
HK1246791A1 (zh) 2018-09-14
KR102557184B1 (ko) 2023-07-18
JP2018504411A (ja) 2018-02-15
WO2016127123A2 (fr) 2016-08-11
AU2016215023A1 (en) 2017-09-07
JP6697808B2 (ja) 2020-05-27
CA2974395C (fr) 2023-08-22
DK3253766T3 (da) 2019-12-09
EP3253766B1 (fr) 2019-09-04
WO2016127123A3 (fr) 2016-10-27
EP3253766A2 (fr) 2017-12-13
AU2016215023B2 (en) 2019-12-19
US20180022756A1 (en) 2018-01-25
US10399994B2 (en) 2019-09-03
ES2760373T3 (es) 2020-05-13
US20160229869A1 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
IL286669A (en) Compounds and methods for modulating tmprss6 expression
EP3265053A4 (fr) Procédés de traitement de la peau
EP3151797A4 (fr) Méthodes et dispositifs de traitement de la peau
EP3634442A4 (fr) Méthodes de traitement et de prévention de maladies
EP3154566A4 (fr) Méthodes et compositions de traitement d'ulcères
EP3310168A4 (fr) Procédés et compositions permettant de traiter des états induits par le virus herpétique
HK1246791A1 (zh) 用於預防或治療感覺毛細胞死亡的化合物和方法
EP3233091A4 (fr) Formulations d'acide hypochloreux et méthodes de traitement des maladies de peau
EP3177292A4 (fr) Composés et méthodes de traitement du cancer
GB201611535D0 (en) Methods and compositions for treating cancer with siglec-9 activity modulators
IL262825A (en) Tetrahydropyridine and tetrahydropyrimidine substances, preparations containing them and their use for pain treatment
EP3519058C0 (fr) Compositions et méthodes de traitement des cheveux
EP3143002A4 (fr) Composés protégeant les neurones, préparation et utilisation de ces derniers
EP3107902A4 (fr) Composés et procédés d'inhibition de la fascine
EP3402575A4 (fr) Procédés et compositions pour le traitement de cheveux endommagés
GB201608779D0 (en) Methods and compounds
EP3113788A4 (fr) Procédés et compositions de protection des cellules sensorielles
GB201608776D0 (en) Methods and compounds
EP3188852A4 (fr) Traitements et procédés de remédiation à auto-régénération
EP3383877A4 (fr) Composés hétérocycliques et leurs utilisations
EP3395323A4 (fr) Procédé de traitement capillaire
EP3358929A4 (fr) Procédés et appareils pour le traitement d'une matière agricole
EP3352729A4 (fr) Méthodes et compositions de traitement de la peau
EP3302458A4 (fr) Méthodes de prévention et de traitement de l'auto-immunité
EP3263109A4 (fr) Médicament pour prévenir et/ou traiter la démence

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170808

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602016019995

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C07D0495140000

Ipc: C07D0495180000

A4 Supplementary search report drawn up and despatched

Effective date: 20180627

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/00 20060101ALI20180621BHEP

Ipc: C07D 495/18 20060101AFI20180621BHEP

Ipc: A61K 31/4743 20060101ALI20180621BHEP

Ipc: A61P 13/12 20060101ALI20180621BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1246791

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190326

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1175171

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190915

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016019995

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20191204

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: NOVAGRAAF INTERNATIONAL SA, CH

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190904

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190904

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190904

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190904

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190904

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190904

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190904

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190904

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200106

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190904

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2760373

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200513

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190904

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200224

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190904

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190904

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016019995

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG2D Information on lapse in contracting state deleted

Ref country code: IS

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200105

26N No opposition filed

Effective date: 20200605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190904

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190904

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200205

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1175171

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190904

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190904

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190904

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190904

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190904

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20220728 AND 20220803

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: ORICULA THERAPEUTICS LLC; US

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE; FORMER OWNER NAME: UNIVERSITY OF WASHINGTON

Effective date: 20220830

Ref country code: NL

Ref legal event code: HC

Owner name: ORICULA THERAPEUTICS LLC; US

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME; FORMER OWNER NAME: UNIVERSITY OF WASHINGTON

Effective date: 20220830

REG Reference to a national code

Ref country code: AT

Ref legal event code: PC

Ref document number: 1175171

Country of ref document: AT

Kind code of ref document: T

Owner name: ORICULA THERAPEUTICS LLC, US

Effective date: 20230320

Ref country code: AT

Ref legal event code: PC

Ref document number: 1175171

Country of ref document: AT

Kind code of ref document: T

Owner name: FRED HUTCHINSON CANCER CENTER, US

Effective date: 20230320

Ref country code: AT

Ref legal event code: PC

Ref document number: 1175171

Country of ref document: AT

Kind code of ref document: T

Owner name: UNIVERSITY OF WASHINGTON, US

Effective date: 20230320

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230519

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240108

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240307

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240125

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20231229

Year of fee payment: 9

Ref country code: GB

Payment date: 20240108

Year of fee payment: 9

Ref country code: CH

Payment date: 20240301

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20240103

Year of fee payment: 9

Ref country code: IT

Payment date: 20240111

Year of fee payment: 9

Ref country code: FR

Payment date: 20240103

Year of fee payment: 9

Ref country code: DK

Payment date: 20240214

Year of fee payment: 9

Ref country code: BE

Payment date: 20240105

Year of fee payment: 9